Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hehe Shuyang Fang (和合疏养方) is a Traditional Chinese Medicine (TCM) granule formulation developed by the Beijing Hospital of Traditional Chinese Medicine, specifically by the team led by Professor Liu Qingquan. Rooted in the "Hehe" (Harmony) philosophy of TCM, the formula was designed to address the convalescent phase of COVID-19 and other viral respiratory illnesses. It aims to "soothe and nourish" the body by tonifying Qi, harmonizing the middle jiao (spleen and stomach), and clearing lingering heat or dampness. Clinical use in China has focused on alleviating post-viral symptoms such as fatigue, palpitations, and digestive disturbances. As a "hospital preparation" (院内制剂), it is authorized for use within specific medical institutions in Beijing to support patient rehabilitation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hehe Shuyang Fang.